Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

Related Articles by Review for PubMed (Select 22890751)

1.

Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer.

Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L.

Breast Cancer Res Treat. 2012 Sep;135(2):619-27. doi: 10.1007/s10549-012-2194-2. Epub 2012 Aug 14.

PMID:
22890751
2.

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Gibson LJ, Dawson C, Lawrence DH, Bliss JM.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD003370.

PMID:
17253488
3.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

PMID:
18705406
4.

Predicting endocrine therapy responsiveness in breast cancer.

Ma CX, Sanchez CG, Ellis MJ.

Oncology (Williston Park). 2009 Feb;23(2):133-42. Review.

5.

Breast cancer in men.

Buzdar AU.

Oncology (Williston Park). 2003 Oct;17(10):1361-4; discussion 1364, 1369-72. Review.

6.

New approaches in the management of male breast cancer.

Patten DK, Sharifi LK, Fazel M.

Clin Breast Cancer. 2013 Oct;13(5):309-14. doi: 10.1016/j.clbc.2013.04.003. Epub 2013 Jul 9. Review.

PMID:
23845572
7.

Challenges in defining predictive markers for response to endocrine therapy in breast cancer.

Larionov AA, Miller WR.

Future Oncol. 2009 Nov;5(9):1415-28. doi: 10.2217/fon.09.113. Review.

PMID:
19903069
8.

Metastasis dormancy in estrogen receptor-positive breast cancer.

Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK.

Clin Cancer Res. 2013 Dec 1;19(23):6389-97. doi: 10.1158/1078-0432.CCR-13-0838. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk